| Patient | Rachel Carson |
|---|---|
| Date of birth | 1907-05-27 |
| Identifiers | MRN HR-ML041-SYN-TD; SSN (made up) 000-41-5068 |
| Document date | 1960-07-20 |
| Author | Margaret Vance-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Blocked nose, facial pressure, and cough for five days. [S]
Ms. Carson is a 53-year-old woman with stage IIB hormone receptor-positive left breast cancer, five weeks into letrozole and on day 8 of her second 28-day cycle of ribociclib. Five days ago she developed a blocked nose, clear then yellow discharge, pressure over both cheeks, a sore throat, and a dry cough. She has had no fever on her home thermometer, checked twice a day as the oncology team taught her, and no chills, breathlessness, or chest pain. The symptoms are no worse than three days ago. She has used saline spray. She called the oncology nurse line, who asked her to be seen today with a blood count. She wanted to know whether this was dangerous on ribociclib and whether she should stop it, and asked for a plain answer. [S]
| Element | Detail |
|---|---|
| Onset | Five days ago |
| Location | Nose, both cheeks, throat |
| Duration | Five days, not worsening |
| Character | Congestion, colored discharge, facial pressure, dry cough |
| Severity | Mild to moderate; writing most mornings |
| Context | Day 8 of ribociclib cycle 2; letrozole daily |
| Modifying factors | Saline spray helps a little |
| Associated signs and symptoms | No fever, breathlessness, chest pain, or ear pain |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever or chills |
| Ears, nose, mouth, and throat | Positive | Blocked nose, colored discharge, cheek pressure, sore throat |
| Respiratory | Positive | Dry cough; no breathlessness or wheeze |
| Cardiovascular | Negative | No palpitations, fainting, or chest pain |
| Gastrointestinal | Negative | No diarrhea, mouth sores, or abdominal pain |
| Integumentary | Negative | No rash; radiation skin healed |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth once daily before breakfast, to complete eight weeks of ulcer healing | One capsule once daily before breakfast | Oral route | 1960-01-19 to 1960-04-03 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 1959-06-02 | active | S |
| Letrozole 2.5 mg oral tablet, one tablet by mouth once daily, planned for at least five years | One tablet once daily | Oral route | 1960-06-15 | active | S |
| Ribociclib 200 mg oral tablet, two tablets (400 mg) by mouth once daily on days 1 to 21 of each 28-day cycle, with letrozole, planned for three years | Two tablets once daily on days 1 to 21 of each 28-day cycle | Oral route | 1960-06-15 | active | S |
| Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every six months for three years | One infusion every six months | Intravenous route | 1960-06-15 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 1960-06-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1960-07-20 | Body height | 163 | cm | S |
| 1960-07-20 | Body weight | 59.2 | kg | S |
| 1960-07-20 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 1960-07-20 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1960-07-20 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1960-07-20 | Heart rate | 82 | /min | S |
| 1960-07-20 | Respiratory rate | 16 | /min | S |
| 1960-07-20 | Body temperature | 37.3 | Cel | S |
| 1960-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1960-07-20 | Leukocytes [#/volume] in Blood by Automated count | 2.9 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1960-07-20 | Neutrophils [#/volume] in Blood by Automated count | 1.2 | 10*3/uL | 1.8-7.7 10*3/uL | Low | S |
| 1960-07-20 | Hemoglobin [Mass/volume] in Blood | 12.2 | g/dL | 12-15.5 g/dL | Normal | S |
| 1960-07-20 | Platelets [#/volume] in Blood by Automated count | 168 | 10*3/uL | 150-400 10*3/uL | Normal | S |
Vital signs recorded on 1960-07-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired but well-appearing; temperature 37.3 °C |
| Ears, nose, and throat | Swollen nasal lining with mucopurulent discharge; mild tenderness over both maxillary sinuses; throat mildly red without exudate; ear drums normal; no mouth ulcers |
| Neck | Small tender anterior cervical nodes; no supraclavicular nodes |
| Respiratory | Clear on both sides; oxygen saturation 98 percent |
| Cardiovascular | Regular rhythm, 82/min |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the left breast, upper outer quadrant at 2 o'clock, 2.4 cm on imaging; core biopsy grade 2, estrogen and progesterone receptor positive, HER2 negative, Ki-67 22 percent; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern counterpart of the documented 1894 breast cancer, which was not disclosed to her | active | confirmed | C50.412 | S — Synthetic tumor details, stage, and treatment; the breast lumps, the 1960 operation, and the nondisclosure are documented (D), but no tumor details from her lifetime are used. |
| Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 80 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no receptor status from her lifetime is known. |
| New firm lump in the upper outer quadrant of the left breast, found two weeks ago; clinically suspicious; diagnostic imaging and biopsy booked | resolved | confirmed | N63.21 | S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the lumps in the left breast in early 1960 are documented (D). |
| Duodenal ulcer found at endoscopy seven weeks ago, with Helicobacter pylori on biopsy; treated with 14 days of bismuth quadruple therapy and completing eight weeks of omeprazole; test of cure planned | resolved | confirmed | K26.9 | S — Synthetic modern ulcer; it echoes the ulcer among her documented illnesses, which the sources do not date. |
| Primary osteoarthritis of both knees, mild, with stiffness after long walks on the shore | active | confirmed | M17.0 | S — Synthetic condition; it is not linked to the documented word arthritis, which she may have used to keep her cancer private. |
| Metastatic carcinoma in two of three left axillary sentinel lymph nodes (macrometastases, no extranodal extension); pathologic stage pT2 pN1a(sn) M0, anatomic stage IIB; recurrence score 17 | active | confirmed | C77.3 | S — Synthetic surgical pathology; spread to lymph nodes is documented later in her life, but no pathology from her lifetime is used. |
| Long-term use of letrozole as adjuvant endocrine therapy, with ribociclib for three years | active | confirmed | Z79.811 | S — Synthetic treatment status. |
| Low bone mass (osteopenia) on baseline DXA before letrozole: lumbar spine T-score -1.8, femoral neck -1.3; 10-year major osteoporotic fracture risk about 7 percent (FRAX); vitamin D insufficiency | active | confirmed | M85.80 | S — Synthetic finding on the baseline DXA the protocol requires for an aromatase inhibitor. |
| Acute viral rhinosinusitis for five days while on ribociclib, with expected grade 2 neutropenia (absolute neutrophil count 1.2) and no fever; resolved with saline irrigation | resolved | confirmed | J01.90 | S — Synthetic common illness; it echoes the sinus infection among her documented illnesses, which the sources do not date, and is not linked to that claim. |
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); KISQALI (ribociclib) tablets: prescribing information (dosage for early breast cancer; QT, hepatotoxicity, and neutropenia monitoring) (2026); IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clin Infect Dis 2012;54(8):e72-e112 (2012)
Follow-up: Telephone check in three days. Return if symptoms pass ten days or worsen. Oncology blood count at the start of the next cycle. Next scheduled visit 1960-09-08: monitoring visit at the start of the fourth ribociclib cycle. [S]